Allakos Inc., a San Francisco Bay Area-based biotechnology company, has completed a $32m Series A financing.
The round was led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
In conjunction with the funding, Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander, PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the company’s Board of Directors.
Led by Christopher Bebbington, DPhil, Founder and CEO, Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 (Th2) immune response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells.
The company intends to use the proceeds to advance its lead program towards targeting cell types implicated in allergic and inflammatory responses to clinical proof-of-concept.
FinSMEs
17/12/2012